Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
Study completion expected in Q1 2028
Allschwil, Switzerland, July 29, 2025
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the initiation of FORWARD-IM, a phase 3 registrational study evaluating the efficacy and safety of its broad-spectrum antifungal fosmanogepix for the treatment of adult patients with invasive mold infections.[1]
Fosmanogepix is a first-in-class antifungal with a novel mechanism of action and is available in both intravenous and oral formulations. It has been evaluated for efficacy and safety in a phase 1 and phase 2 program, including three open-label phase 2 studies for the treatment of Candidemia, including Candida auris , and invasive mold infections.[2, 3, 4, 5, 6]
The FORWARD-IM study is the second phase 3 study for fosmanogepix, following the initiation of FAST-IC in September 2024, a randomized, double-blind phase 3 registrational study in adult patients with candidemia and/or invasive candidiasis.[7]
Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: 'Our phase 3 program with fosmanogepix allows us to fully explore the clinical benefit of this important new treatment option for invasive fungal infections. Its broad-spectrum activity against multidrug-resistant molds and yeasts highlights the unique potential of fosmanogepix to address significant gaps in current antifungal therapies. Fosmanogepix has shown promising efficacy in earlier clinical studies and in the ongoing expanded access program. The initiation of our second phase 3 study is a significant milestone for fosmanogepix and demonstrates our commitment to advancing our innovative pipeline for the benefit of patients.'
FORWARD-IM is an interventional, open-label, two-cohort phase 3 study in adult patients with invasive mold infections caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans , Mucorales fungi, or other multidrug-resistant molds. The first cohort will enroll approximately 160 patients, randomized in a 2:1 ratio to receive either fosmanogepix or current standard-of-care therapy. The second cohort will enroll approximately 60 patients who have developed intolerance, toxicities, lack of clinical response, or whose fungal isolate is resistant to standard-of-care therapy. All patients in the second cohort will receive fosmanogepix. The completion of the study and publication of results are expected in 2028. The Swiss-based global company PSI CRO AG is managing the phase 3 program.
Basilea acquired fosmanogepix from Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc. Pfizer retains a right of first negotiation for commercializing fosmanogepix, once phase 3 development is successfully completed.
This project is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The contract and federal funding are not an endorsement of the study results, product, or company.
About fosmanogepix
Fosmanogepix is a clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus , including multi-drug-resistant strains, such as Candida auris and Candida glabrata , as well as rare difficult-to-treat molds including Fusarium spp., Lomentospora prolificans , Scedosporium spp., and some fungi from the Mucorales order.[2] Fosmanogepix intravenous and oral formulations have been evaluated in phase 2 studies for the treatment of patients with Candidemia, including Candida auris , and invasive mold infections.[4, 5, 6] Fosmanogepix has received Fast Track and Orphan Drug designations from the US Food and Drug Administration (FDA) for seven separate indications, and is designated as a Qualified Infectious Disease Product (QIDP).
About invasive mold infections
Invasive aspergillosis and invasive infections with rare molds (e.g., Fusarium spp., Lomentospora prolificans , Scedosporium spp., and Mucorales fungi) are life-threatening infections that predominantly affect immunocompromised patients, including patients with hematologic malignancies (blood cancer), transplant patients, or patients with other immunodeficiency disorders. These infections are associated with high morbidity and mortality.[8, 9]
About invasive candidiasis
Invasive candidiasis, including deep-seated tissue candidiasis and candidemia, is an increasingly important nosocomial infection, especially in patients hospitalized in intensive care units. Candida species are ranked as the fourth main cause of bloodstream infections in hospitals in the US.[10] The prognosis of invasive candidiasis remains unfavorable, with a reported mortality rate as high as 40%, even when patients receive antifungal therapy.[11]
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as 'believe', 'assume', 'expect', 'forecast', 'project', 'may', 'could', 'might', 'will' or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
This press release can be downloaded from www.basilea.com.
References FORWARD-IM (FOsmanogepix study Run Worldwide as Antifungal treatment in Resistant Disease caused by Invasive Molds): ClinicalTrials.gov identifier: NCT06925321 K. J. Shaw, A. S. Ibrahim. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections. Journal of Fungi (Basel) 2020 (6), 239 M. R. Hodges, E. Ople, P. Wedel et al. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers. Antimicrobial Agents and Chemotherapy 2023 (67), e01623-22 J. A. Vazquez, P. G. Pappas, K. Boffard et al. Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial. Antimicrobial Agents and Chemotherapy2023 (67), e01419-22 P. G. Pappas, J. A. Vazquez, I. Oren et al. Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial. Journal of Antimicrobial Chemotherapy 2023 (78), 2471-2480 M.R. Hodges, M. Tawadrous, O.A. Cornely et al. Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). Clinical Infectious Diseases 2025 Apr 9:ciaf185 FAST-IC (Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis): ClinicalTrials.gov identifier: NCT05421858 J. Cadena, G. R. Thompson 3rd, T. F. Patterson. Aspergillosis: Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of North America 2021 (35), 415-434 M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clinical Microbiology and Infection 2015 (21), 490.e1-490.e10 Candidemia (Blood Infection) and Other Candida Infections. 2019 Factsheet by the American Thoracic Society: https://www.thoracic.org/patients/patient-resources/resources/candidemia.pdf (Accessed: July 28, 2025) B. J. Kullberg, M. C. Arendrup. Invasive Candidiasis. The New England Journal of Medicine 2015 (373), 1445-1456
Attachment
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Bitcoin Swift Opens Final 5 Days of Stage 3 Presale With Real-Time Passive Yield and Zero Lockups
By GlobeNewswire Published on August 3, 2025, 18:28 IST LUXEMBOURG, Aug. 03, 2025 (GLOBE NEWSWIRE) — Bitcoin Swift (BTC3), a programmable passive yield protocol, has entered the final five days of Stage 3 in its 64-day presale, which is set to end on September 18, 2025. The current price of BTC3 stands at $3, with Stage 4 expected to increase to $4. BTC3 is confirmed to list at $15 on Orca DEX ( Bitcoin Swift has attracted attention for its real-time, on-chain Proof of Yield (PoY) system, which distributes rewards automatically at the end of each presale stage. Unlike many blockchain reward systems that require token lockups or vesting, BTC3 allows full liquidity and access to earned rewards from the start. Key Highlights of Bitcoin Swift's PoY System Real-Time PoY : BTC3 rewards are dynamically adjusted based on user activity and clean energy metrics. Rewards are issued automatically at the end of each presale stage via smart contracts. : BTC3 rewards are dynamically adjusted based on user activity and clean energy metrics. Rewards are issued automatically at the end of each presale stage via smart contracts. No Lockups : Participants can access their funds and rewards without vesting schedules or delays. : Participants can access their funds and rewards without vesting schedules or delays. AI Integration : The protocol uses AI agents to monitor carbon efficiency and optimize network engagement. These inputs affect reward distribution in real time. : The protocol uses AI agents to monitor carbon efficiency and optimize network engagement. These inputs affect reward distribution in real time. Stablecoin Utility : BTC3E, an overcollateralized stablecoin, is backed by locked BTC3 tokens and managed by AI-powered oracles to ensure price stability. : BTC3E, an overcollateralized stablecoin, is backed by locked BTC3 tokens and managed by AI-powered oracles to ensure price stability. Security Audits: Protocol audits have been completed by Spywolf and Solidproof , and KYC verification has been conducted via Spywolf KYC . The Stage 3 presale offers a 121% APY in programmable PoY rewards, which will be distributed at the end of the stage. These rewards are earned directly on-chain with no manual intervention or withdrawal delays. Upcoming Milestones Q3–Q4 2025 : Presale completion, Solana deployment, and PoY reward issuance : Presale completion, Solana deployment, and PoY reward issuance Q1 2026 : Launch of AI-based contract engine and adaptive agents : Launch of AI-based contract engine and adaptive agents Q2 2026 : zk-ledger release, shielded DeFi beta, and zkLogin integration : zk-ledger release, shielded DeFi beta, and zkLogin integration Q3 2026 : Governance rollout with AI voting simulator : Governance rollout with AI voting simulator Q4 2026: BTC3 mainnet, BTC3E stablecoin launch, and institutional onboarding The BTC3 protocol was designed to align with emerging trends in programmable rewards and environmental metrics. Its presale structure enables early participants to benefit from immediate, auto-distributed yield while maintaining token liquidity. For more information about Bitcoin Swift, visit: Website: Contact:Luc Schaus [email protected] Disclaimer: This content is provided by Bitcoin Swift. The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page. Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Images accompanying this announcement are available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
3 hours ago
- Business Upturn
Eliquid Base Launches Compliant Prefilled Pod Kit as Legal Alternative to Banned Disposable Vapes in the UK
By GlobeNewswire Published on August 3, 2025, 21:56 IST MANCHESTER, United Kingdom, Aug. 03, 2025 (GLOBE NEWSWIRE) — With the UK government's 2025 disposable vape ban now in effect to tackle environmental concerns and reduce health risks, millions of vapers are left seeking legal and reliable alternatives. Eliquid Base, one of the UK's leading online vape retailers, has stepped up with a robust solution; the launch of compliant prefilled pod kits that align with UK TPD regulations, offering the same convenience and flavour experience as disposables without breaching the new rules. Game-Changing Solution for Vapers The newly introduced prefilled pod kits by Eliquid Base are designed to replicate the user-friendly nature of disposables while being rechargeable, sustainable, and eco-conscious. Devices like the Hayati Pro Ultra Plus 25000 , Hayati 50k , and Lost Mary BM6000 are excellent examples of next-generation prefilled kits delivering high puff counts, USB-C charging, and easy pod replacements that require no maintenance or complex setup. These kits cater specifically to those who previously relied on disposable vapes for their portability, simplicity, and flavour variety. Now, users can experience the same satisfaction by swapping pods instead of throwing away entire devices; a win for both users and the environment. A Seamless Transition With Familiar Brands Eliquid Base ensures the transition from disposables to pod kits is smooth by offering fan-favourite brands and flavours already trusted by UK vapers. Customers can choose from a wide range of compatible pods, including the Hayati Pro Max 6000 Pods and Lost Mary BM6000 Pods, delivering the same rich flavour profiles as their disposable counterparts. To enhance the vaping experience, users can pair these devices with top-selling nicotine salts or e-liquids or vape juice such as: These nicotine salts are TPD-compliant, available in various popular flavours, and provide a smooth throat hit with fast nicotine delivery; making them ideal for mouth-to-lung pod systems. Pod Compatibility for Custom Vaping In addition to Vape kits, Eliquid Base also supports refillable pod devices for users who prefer more flexibility and longer-term use. Leading pod systems such as the Vaporesso XROS Pods, Geekvape Pods, and OXVA Pods are also available; perfect for pairing with Eliquid Base's expansive nic salt e-liquid range. Key Features of Compliant Prefilled Pod Kits Fully TPD-compliant and legally sold in the UK Eco-friendly: reduces disposable waste Rechargeable via USB-C for extended use Pod-based systems with simple replacements Compatible with premium nicotine salts More affordable than disposables over time No buttons, settings, or refilling needed; just plug and vape Final Thoughts The disposable vape ban may mark the end of an era, but it also opens the door to better, smarter, and more sustainable vaping solutions. With products like the Hayati Pro Ultra Plus 25000, Hayati Pro Max Plus 6000, Lost Mary BM6000, and nic salts from top UK brands, Eliquid Base is proud to lead the charge with fully compliant pod kits that meet both regulatory and consumer expectations. Contact Us 0161 394 1224 [email protected] CP TECH INTERNATIONAL LTD Company No: 12498420, UNIT 2, EURO HOUSE, 1 Overbridge Road, Salford M7 1SL, Manchester Disclaimer: This content is provided by Eliquid Base. The statements, views, and opinions expressed in this column are solely those of the content provider. This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
3 hours ago
- Business Upturn
Presentation Explores the Engineering Behind Starlink's Global Internet Network
Baltimore, MD, Aug. 03, 2025 (GLOBE NEWSWIRE) — Presentation featuring entrepreneur James Altucher dives into the advanced engineering driving Elon Musk's Starlink project and how its satellite network could mark a fundamental shift in communications technology. 'Starlink is the radical new future of the internet,' Altucher says in the presentation. 'It beams fast, reliable, unlimited internet through the air… directly to your device.' Building a 'Mesh' in Space The presentation details how thousands of interconnected satellites in low-Earth orbit create a dynamic, self-adjusting mesh network. 'Elon's satellites are designed to wrap the Earth, forming a network to deliver lightning-fast internet to every inch of the planet,' Altucher explains. This configuration allows data to bypass ground-based congestion and maintain low latency even across vast distances. Next-Generation User Equipment At the device level, the presentation spotlights Starlink's terminal design, which uses electronically steered phased-array antennas. 'This antenna is likely built using parts from one small, off-the-radar company,' Altucher notes This technology allows seamless satellite handoffs and enables stable connectivity on moving platforms such as ships and aircraft. Resilient by Design The presentation underscores Starlink's ability to maintain service in extreme conditions. 'It's being used in the Ukraine conflict, where all other access to internet service has been cut off,' Altucher states, highlighting the network's value as a backup communications grid when traditional infrastructure fails. Scaling Without Ground Constraints By avoiding traditional cabling and tower construction, the presentation suggests Starlink's architecture could make high-speed connectivity accessible at unprecedented scale and cost efficiency. 'There'd be no need to dig up neighborhoods, install cables or build cell towers — all of which cost hundreds of billions of dollars,' Altucher explains. He points to this as the foundation for connecting the remaining billions worldwide who are currently offline. About James Altucher James Altucher is a technology entrepreneur, venture capitalist, and Wall Street Journal bestselling author known for identifying transformative innovations years ahead of the mainstream. Recognized as 'one of the best venture capitalists, angel investors, and tech entrepreneurs in the world', he has been an early supporter of disruptive technologies in streaming, social media, and cryptocurrency. He leads Altucher's Investment Network and hosts The James Altucher Show , which has been downloaded more than 40 million times. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
